MD117Y - Method for treating the neovascular glaucoma - Google Patents

Method for treating the neovascular glaucoma

Info

Publication number
MD117Y
MD117Y MDS20090137A MDS20090137A MD117Y MD 117 Y MD117 Y MD 117Y MD S20090137 A MDS20090137 A MD S20090137A MD S20090137 A MDS20090137 A MD S20090137A MD 117 Y MD117 Y MD 117Y
Authority
MD
Moldova
Prior art keywords
neovascular glaucoma
treating
treatment
fistulizing
paracentesis
Prior art date
Application number
MDS20090137A
Other languages
Romanian (ro)
Inventor
Valeriu Cusnir
Aurel Rusu
Vitalie Cusnir
Original Assignee
Valeriu Cusnir
Aurel Rusu
Vitalie Cusnir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeriu Cusnir, Aurel Rusu, Vitalie Cusnir filed Critical Valeriu Cusnir
Priority to MDS20090137A priority Critical patent/MD117Z/en
Publication of MD117Y publication Critical patent/MD117Y/en
Publication of MD117Z publication Critical patent/MD117Z/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inventia se refera la medicina si poate fi utilizata pentru tratamentul glaucomului neovascular. Metoda de tratament al glaucomului neovascular consta in aceea ca in camera anterioara a ochiului sub anestezie locala prin paracenteza corneei se injecteaza 0,1 ml de solutie de avastin de 2,5%, apoi in sacul conjunctival se instileaza un antibiotic si se aplica un pansament steril pe ochi pentru o zi, dupa care peste 1...4 zile se efectueaza operatia fistulizanta.The invention relates to medicine and can be used for the treatment of neovascular glaucoma. The treatment method of neovascular glaucoma consists in the fact that in the anterior chamber of the eye under local anesthesia by paracentesis of the cornea, 0.1 ml of 2.5% avastin solution is injected, then an antibiotic is instilled in the conjunctival sac and a bandage is applied. sterile on the eyes for one day, after which after 1 to 4 days the fistulizing operation is performed.

MDS20090137A 2009-07-21 2009-07-21 Method for treating the neovascular glaucoma MD117Z (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20090137A MD117Z (en) 2009-07-21 2009-07-21 Method for treating the neovascular glaucoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20090137A MD117Z (en) 2009-07-21 2009-07-21 Method for treating the neovascular glaucoma

Publications (2)

Publication Number Publication Date
MD117Y true MD117Y (en) 2009-12-31
MD117Z MD117Z (en) 2010-07-31

Family

ID=43568874

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20090137A MD117Z (en) 2009-07-21 2009-07-21 Method for treating the neovascular glaucoma

Country Status (1)

Country Link
MD (1) MD117Z (en)
  • 2009

Also Published As

Publication number Publication date
MD117Z (en) 2010-07-31

Similar Documents

Publication Publication Date Title
EA201000441A1 (en) AQUATIC OPHTHALMIC PREPARATIONS
BRPI0608152A2 (en) eye care formulations
NZ718955A (en) Compositions comprising povidone-iodine
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2022007276A (en) Treatment of amyotrophic lateral sclerosis and related disorders.
MX2010009623A (en) 1-benzyl-3-hydroxymethylindazoiî¹e derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1.
AR109103A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
MY170198A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
MX2009001745A (en) Treatment of ocular diseases.
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
MX2024000828A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis.
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
MX2016001457A (en) Corneal endothelium ecm therapeutic drug.
AR092842A1 (en) TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
EA201290827A1 (en) OPHTHALMOLOGICAL SOLUTION FOR THE TREATMENT OF EYE INFECTION, CONTAINING THE HEADLOOK FOXES OF THE OTHER HEADS, OR ITS SALT, OR SOLVAT OF THESE CONNECTIONS, THE METHOD OF TREATING THE EYE INFECTION, LEVOFLOXACINE OR THE EFFICIENT CONFIGURATIONS
MD117Y (en) Method for treating the neovascular glaucoma
EA201170970A1 (en) DEFERIPRON APPLICATION FOR TREATMENT AND PREVENTION OF EYE DISEASES ASSOCIATED WITH IRON
MX2022006523A (en) Composition comprising budesonide for ophthalmic use.
MX2022012001A (en) Preventative treatment of migraine.
MY145266A (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
EA201690903A1 (en) TREATMENT GLAUCOMA USING LAQUINIMODE
FI3519050T3 (en) Compositions for treating ophthalmic conditions
WO2022148016A9 (en) Method for treating ocular surface diseases

Legal Events

Date Code Title Description
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)
MM4Y Short-term patent definitely lapsed due to non-payment of fees